Last 12 months
Inside the activity.
82 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 3 | 0 |
| Dec 2025 | 25 | 0 |
| Jan 2026 | 10 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 14 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 15 | 0 |
| Sep 2026 | 15 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2020 Filed Dec 31, 2020 22:22 UTC |
Rubini Jonathan Brian10% owner
|
OtherCommon Stock | 4,074,074 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-045804 · ownership.xml · nonDerivative · entry 1 Rubini Jonathan Brian · CIK 0001723667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,529,813 F1 · price: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:01 UTC |
Zarzewsky JosephDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-021854 · ownership.xml · derivative · entry 1 Zarzewsky Joseph · CIK 0001723700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of the grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of the grant. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 16:02 UTC |
SIECZKAREK MARK MDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-021855 · ownership.xml · derivative · entry 1 SIECZKAREK MARK M · CIK 0001188738 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of the grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of the grant. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:04 UTC |
Keret YosefDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-021857 · ownership.xml · derivative · entry 1 Keret Yosef · CIK 0001722972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of the grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of the grant. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:00 UTC |
Belkin MichaelDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-20-021850 · ownership.xml · derivative · entry 1 Belkin Michael · CIK 0001580801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of the grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of the grant. Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:31 UTC |
Rubini Jonathan Brian10% owner
|
PurchaseWarrants · Derivative | 4,074,047 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001213900-19-027008 · ownership.xml · derivative · entry 2 Rubini Jonathan Brian · CIK 0001723667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,074,047 Underlying: Common Stock · 4,074,047 shares Expires 2024-12-19 F1 · derivative.exercise_date: Exercisable five days following the public announcement of positive clinical data results for LO2A Read SEC document |
| December 20, 2019 Filed Dec 26, 2019 21:31 UTC |
Rubini Jonathan Brian10% owner
|
PurchaseCommon Stock | 2,037,037 | $0.27 | $549,999.99 |
DisclosureSEC source: 0001213900-19-027008 · ownership.xml · nonDerivative · entry 1 Rubini Jonathan Brian · CIK 0001723667 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,455,739 Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:58 UTC |
Danenberg NoamChief Executive Officer
|
OtherFuture Investment Rights · Derivative | 31,146 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001213900-19-026353 · ownership.xml · derivative · entry 3 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 94,382 Underlying: Common Stock · 31,146 shares Expires 2024-12-12 F4 · ownership.nature: Securities held by Mobigo Inc. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:58 UTC |
Danenberg NoamChief Executive Officer
|
OtherWarrants · Derivative | 1,505,162 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001213900-19-026353 · ownership.xml · derivative · entry 2 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,505,162 Underlying: Common Stock · 1,505,162 shares Expires 2024-12-12 F3 · derivative.exercise_date: Exercisable five days following the public announcement of positive clinical data results for LO2A F4 · ownership.nature: Securities held by Mobigo Inc. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:58 UTC |
Danenberg NoamChief Executive Officer
|
ConversionCommon Stock | 752,581 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-026353 · ownership.xml · nonDerivative · entry 1 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 952,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Outstanding debt converted at $0.27 per share. F2 · ownership.nature: 752,581 shares held by Mobigo Inc. and 200,100 previously held shares directly. Read SEC document |
| December 13, 2019 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
OtherFuture Investment Rights · Derivative | 350,334 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 7 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,334 Underlying: Common Stock · 350,334 shares Expires 2024-12-12 F12 · shares: Future investment rights to purchase 350,334 shares of Common Stock terminated upon the Company paying the remaining aggregate $457,004 outstanding under the 2016 Convertible Notes and the 2017 Convertible Notes. Read SEC document |
| December 13, 2019 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
PurchaseCommon Stock Warrants · Derivative | 3,385,212 | $0.00 Strike: $0.27 | $0.00 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 6 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,385,212 Underlying: Common Stock · 3,385,212 shares Expires 2024-12-12 F11 · derivative.exercise_date: Exercisable five days following the public announcement of positive clinical data results for LO2A (such warrants, the "Conversion Warrants"). Read SEC document |
| December 13, 2019 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
ConversionCommon Stock | 1,692,606 | $0.27 | $457,003.62 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · nonDerivative · entry 2 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,966,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Acquired upon conversion of an aggregate of $457,004 of the 2016 Convertible Notes and the 2017 Convertible Notes at an adjusted conversion price of $0.27 per share. F8 · balance_after: Represents (i) 2,310,048 shares of Common Stock, (ii) 400,000 shares of Common Stock issuable upon exercise of Series A Warrants, (iii) 3,385,212 shares of Common Stock issuable upon exercise of the Conversion Warrants (as defined below), (iii) 520,820 shares of Common Stock issuable upon exercise of the Loan Extension Warrants (as defined below), and (iv) 350,334 shares of Common Stock issuable upon exercise of Future Investment Rights. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 17:12 UTC |
Zarzewsky JosephDirector
|
Exercise / conversionRestricted Stock Units (RSU) · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018167 · ownership.xml · derivative · entry 2 Zarzewsky Joseph · CIK 0001723700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 17:12 UTC |
Zarzewsky JosephDirector
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018167 · ownership.xml · nonDerivative · entry 1 Zarzewsky Joseph · CIK 0001723700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:20 UTC |
Keret YosefDirector
|
Exercise / conversionRestricted Stock Units (RSU) · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018178 · ownership.xml · derivative · entry 2 Keret Yosef · CIK 0001722972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:20 UTC |
Keret YosefDirector
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018178 · ownership.xml · nonDerivative · entry 1 Keret Yosef · CIK 0001722972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:18 UTC |
Eisenberg OrCOO, CFO, Treas & Secy.
|
Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018176 · ownership.xml · derivative · entry 2 Eisenberg Or · CIK 0001721412 · COO, CFO, Treas & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,600 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 140,000 restricted stock units, vesting quarterly over a two year period commencing on the date of grant with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 140,000 restricted stock units, vesting quarterly over a two year period commencing on the date of grant with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:18 UTC |
Eisenberg OrCOO, CFO, Treas & Secy.
|
Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018176 · ownership.xml · nonDerivative · entry 1 Eisenberg Or · CIK 0001721412 · COO, CFO, Treas & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:16 UTC |
Danenberg NoamChief Executive Officer
|
Exercise / conversionRestricted Stock Units (RSU) · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018174 · ownership.xml · derivative · entry 2 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,500 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 140,000 restricted stock units, vesting quarterly over a two-year period with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 140,000 restricted stock units, vesting quarterly over a two-year period with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:16 UTC |
Danenberg NoamChief Executive Officer
|
Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018174 · ownership.xml · nonDerivative · entry 1 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:14 UTC |
Belkin MichaelDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018172 · ownership.xml · derivative · entry 2 Belkin Michael · CIK 0001580801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:14 UTC |
Belkin MichaelDirector
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018172 · ownership.xml · nonDerivative · entry 1 Belkin Michael · CIK 0001580801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:13 UTC |
Franck AmouyalDirector
|
Exercise / conversionRestricted Stock Units (RSU) · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-018170 · ownership.xml · derivative · entry 2 Franck Amouyal · CIK 0001723469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. F2 · derivative.expiration_date: On March 31, 2019, the reporting person was granted 100,000 restricted stock units, vesting quarterly over a two year period with the first installment issued on June 30, 2019. Read SEC document |
| June 30, 2019 Filed Sep 16, 2019 21:13 UTC |
Franck AmouyalDirector
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-19-018170 · ownership.xml · nonDerivative · entry 1 Franck Amouyal · CIK 0001723469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. Read SEC document |
| May 31, 2019 Filed Jun 10, 2019 21:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseWarrants · Derivative | 173,607 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001213900-19-010439 · ownership.xml · derivative · entry 1 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 173,607 Underlying: Common Stock · 173,607 shares Expires 2021-05-30 F1 · price: Issued as consideration for extending by 6 months the maturity date of loans made to the Issuer. F2 · ownership.nature: Held by Mr. Danenberg's wholly-owned company Mobigo Inc. Read SEC document |
| May 31, 2019 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
OtherCommon Stock Warrants · Derivative | 520,820 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 5 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,820 Underlying: Common Stock · 520,820 shares Expires 2021-05-30 F10 · kind: Issued in consideration for the Reporting Person extending for a term of six months the maturity date of each of the 2016 Convertible Notes and the 2017 Convertible Notes in the aggregate amount of $914,008 (such warrants, the "Loan Extension Warrants"). F10 · price: Issued in consideration for the Reporting Person extending for a term of six months the maturity date of each of the 2016 Convertible Notes and the 2017 Convertible Notes in the aggregate amount of $914,008 (such warrants, the "Loan Extension Warrants"). Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 20:00 UTC |
Ridge Valley Corp10% owner
|
SaleInvestment Rights · Derivative | 94,382 | Not disclosed Strike: $1.33 | Not disclosed |
DisclosureSEC source: 0001213900-19-006996 · ownership.xml · derivative · entry 2 Ridge Valley Corp · CIK 0001722230 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 94,382 shares Expires 2019-11-30 F2 · price: The purchaser waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 20:00 UTC |
Ridge Valley Corp10% owner
|
SaleConvertible Loans · Derivative | 265,531 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001213900-19-006996 · ownership.xml · derivative · entry 1 Ridge Valley Corp · CIK 0001722230 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 265,531 shares Expires 2019-05-31 F2 · price: The purchaser waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities. F1 · derivative.exercise_date: Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 22:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseSeries B Warrants · Derivative | 125,000 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001213900-19-006993 · ownership.xml · derivative · entry 5 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F5 · price: Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000. F6 · derivative.expiration_date: The Series B Warrants expire twenty (20) days following the later of (i) the public announcement of Phase II clinical data for LO2A or (ii) six (6) months following October 23, 2018. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 22:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseSeries A Warrants · Derivative | 125,000 | Not disclosed Strike: $1.10 | Not disclosed |
DisclosureSEC source: 0001213900-19-006993 · ownership.xml · derivative · entry 4 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires not disclosed F5 · price: Purchased together with the 125,000 shares of Common Stock described in Table I for total purchase price of $125,000. F4 · derivative.expiration_date: The Series A Warrants expire sixty (60) months after October 23, 2018. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 22:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseInvestment Rights · Derivative | 94,382 | Not disclosed Strike: $1.33 | Not disclosed |
DisclosureSEC source: 0001213900-19-006993 · ownership.xml · derivative · entry 3 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 94,382 Underlying: Common Stock · 94,382 shares Expires 2019-11-30 F2 · price: Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities. F3 · ownership.nature: Held by Mr. Danenberg's wholly-owned company Mobigo Inc. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 22:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseConvertible Loans · Derivative | 265,531 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001213900-19-006993 · ownership.xml · derivative · entry 2 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 265,531 Underlying: Common Stock · 265,531 shares Expires 2019-05-31 F2 · price: Mr. Danenberg waived a debt owed to him by Ridge Valley Corporation as consideration for these derivative securities. F1 · derivative.exercise_date: Issuable upon the conversion of the convertible loans under the January 19, 2017 Loan Agreement (the "Loan Agreement") by and among the Issuer and Ridge Valley Corporation, among others. The Convertible Loans may be converted at any time. F3 · ownership.nature: Held by Mr. Danenberg's wholly-owned company Mobigo Inc. Read SEC document |
| April 21, 2019 Filed Apr 23, 2019 22:00 UTC |
Danenberg NoamChief Executive Officer
|
PurchaseCommon Stock | 125,000 | $1.00 | $125,000.00 |
DisclosureSEC source: 0001213900-19-006993 · ownership.xml · nonDerivative · entry 1 Danenberg Noam · CIK 0001720898 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,100 Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 20:28 UTC |
Zarzewsky JosephDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005672 · ownership.xml · derivative · entry 1 Zarzewsky Joseph · CIK 0001723700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 00:25 UTC |
Eisenberg OrActing CEO, CFO, Treas & Secy.
|
GrantRestricted Stock Units (RSU) · Derivative | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005669 · ownership.xml · derivative · entry 1 Eisenberg Or · CIK 0001721412 · Acting CEO, CFO, Treas & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,100 Underlying: Common Stock · 140,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 00:27 UTC |
Keret YosefDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005671 · ownership.xml · derivative · entry 1 Keret Yosef · CIK 0001722972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 00:24 UTC |
Danenberg NoamDirector · Chairman
|
GrantRestricted Stock Units (RSU) · Derivative | 140,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005668 · ownership.xml · derivative · entry 1 Danenberg Noam · CIK 0001720898 · Director · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,100 Underlying: Common Stock · 140,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. F3 · balance_after: Includes RSUs issued to Danenberg Holdings. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 00:23 UTC |
Belkin MichaelDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005667 · ownership.xml · derivative · entry 1 Belkin Michael · CIK 0001580801 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 00:18 UTC |
Franck AmouyalDirector
|
GrantRestricted Stock Units (RSU) · Derivative | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-005664 · ownership.xml · derivative · entry 1 Franck Amouyal · CIK 0001723469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a right to receive one share of Wize Pharma, Inc. common stock. F2 · derivative.exercise_date: Vest quarterly over a two year period commencing on the date of grant. F2 · derivative.expiration_date: Vest quarterly over a two year period commencing on the date of grant. Read SEC document |
| October 24, 2018 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
PurchaseSeries B Warrants · Derivative | 400,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 4 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires not disclosed F9 · derivative.expiration_date: The Series B Warrants had a term that expired 20 days following the later of (i) the public announcement of Phase II clinical data for LO2A and (ii) six months following the issuance date, provided that, for each day after the issuance date that an Equity Conditions Failure (as defined in the Series B Warrants) occurred, the expiration date of the Series B Warrants was to be extended by one day. The Series B Warrants expired on April 24, 2019. Read SEC document |
| October 24, 2018 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
PurchaseSeries A Warrants · Derivative | 400,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · derivative · entry 3 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2023-10-24 Read SEC document |
| October 24, 2018 Filed Feb 6, 2020 08:59 UTC |
Rimon Gold Assets Ltd10% owner
|
PurchaseCommon Stock, par value $0.001 per share | 400,000 | $1.00 | $400,000.00 |
DisclosureSEC source: 0001213900-20-002732 · ownership.xml · nonDerivative · entry 1 Rimon Gold Assets Ltd · CIK 0001721808 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,985,483 F1 · balance_after: Represents (i) 617,442 shares of Common Stock, (ii) 603,486 shares of Common Stock then issuable upon the conversion of the 2016 Convertible Notes (as defined below), (iii) 263,887 shares of Common Stock then issuable upon the conversion of the 2017 Convertible Notes (as defined below), (iv) 400,000 shares of Common Stock then issuable upon exercise of Series A Warrants, (v) 400,000 shares of Common Stock then issuable upon exercise of Series B Warrants, (vi) 392,055 shares of Common Stock then issuable upon the exercise of the 2016 Investment Rights (as defined below) and (vii) 308,613 shares of Common Stock then issuable upon the exercise of the 2017 Investment Rights (as defined below). (Continued in Footnote 2) F2 · balance_after: (Continued from Footnote 1) The Reporting Person is an Israeli private company wholly owned by the Goldfinger Trust (the "Trust"), whose trustee is Abir Raveh (the "Trustee") and whose beneficiary is Yair Goldfinger. The Trust directs the management of Rimon Gold, its investment and voting decisions and the Trustee directs the management of the Trust, its investment and voting decisions. F3 · balance_after: (Continued from Footnote 2) The Reporting Person's then-outstanding loan in the principal amount of $531,067, which bore interest at an annual rate of 4% (the "2016 Convertible Notes"), was convertible (including accrued interest) into 605,298 shares of Common Stock based on a conversion price per share of $0.9768. The Reporting Person had the right to invest up to $392,055, in the aggregate, at an agreed price per share of $1.308 (the "2016 Investment Right"). The Reporting Person had the right to invest up to $308,613, in the aggregate, at an agreed price per share of $1.332 (the "2017 Investment Right"). (Continued in Footnote 4) F4 · balance_after: (Continued from Footnote 3) The Reporting Person's then-outstanding loan to the Issuer in the principal amount of $274,048, which bore interest at an annual rate of 4% (the "2017 Convertible Notes"), was convertible (including accrued interest) into 264,709 shares of Common Stock based on a loan conversion price per share of $1.1112. In connection with a private placement consummated by the Issuer in October 2018, on October 19, 2018 the Reporting Person and the other parties thereto entered into an amendment to the 2016 Convertible Notes and the 2017 Convertible Notes (the "Loan Agreements Amendment"). (Continued in Footnote 5) F5 · balance_after: (Continued from Footnote 4) Pursuant to the Loan Agreements Amendment, the maturity date (the "Loan Agreements Maturity Date") under the 2016 Convertible Notes and the 2017 Convertible Notes was amended to be the earliest of (a) 90 days following the date that a registration statement relating to the resale of up to 13,706,000 shares of Common Stock issued or issuable in connection with the October 2018 private placement is declared effective by the U.S. Securities and Exchange Commission, (b) 90 days following the date on which all securities issued to investors in the October 2018 private placement are no longer deemed "registrable securities" under the Registration Rights Agreement entered into in connection with the October 2018 private placement, and (c) October 24, 2019. (Continued in Footnote 6) F6 · balance_after: (Continued from Footnote 5) In addition, pursuant to the Loan Agreements Amendment, the expiration date of the 2016 Investment Right and the 2017 Investment Right was amended to be 180 days after the Loan Agreements Maturity Date. Read SEC document |
| April 04, 2018 Filed May 1, 2018 11:41 UTC |
Zarzewsky JosephDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005275 · f4040418zarzewsky_wizepharma.xml · derivative · entry 1 Zarzewsky Joseph · CIK 0001723700 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-04-04 F2 · price: The Stock Option was granted as compensation for services as a director of the Issuer. F1 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed May 1, 2018 16:04 UTC |
Keret YosefDirector
|
GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005279 · f4040418keret_wizepharma.xml · derivative · entry 1 Keret Yosef · CIK 0001722972 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-04-04 F2 · price: The Stock Option was granted as compensation for services as a director of the Issuer. F1 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:39 UTC |
Mayron RonDirector
|
GrantStock Option (right to buy) · Derivative | 46,500 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005273 · f4040418mayron_wizepharma.xml · derivative · entry 2 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,500 shares Expires 2025-04-04 F4 · price: The Stock Option was granted as compensation for services as the Chairman of the Board of the Issuer. F3 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:39 UTC |
Mayron RonDirector
|
GrantRestricted Stock Units (RSUs) | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-005273 · f4040418mayron_wizepharma.xml · nonDerivative · entry 1 Mayron Ron · CIK 0001722033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,259 F1 · kind: The RSUs were fully vested upon grant. F2 · price: The RSUs were granted as compensation for services as the Chairman of the Board of the Issuer. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:27 UTC |
Eisenberg OrActing CEO, CFO, Treas & Secy.
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005270 · f4040418eisenberg_wizepharma.xml · derivative · entry 2 Eisenberg Or · CIK 0001721412 · Acting CEO, CFO, Treas & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2025-04-04 F4 · price: The Stock Option was granted as compensation for services as the CEO of the Issuer. F3 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:27 UTC |
Eisenberg OrActing CEO, CFO, Treas & Secy.
|
GrantRestricted Stock Units (RSU) | 40,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-005270 · f4040418eisenberg_wizepharma.xml · nonDerivative · entry 1 Eisenberg Or · CIK 0001721412 · Acting CEO, CFO, Treas & Secy. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,100 F1 · kind: The RSUs were fully vested upon grant. F2 · price: The RSUs were granted as compensation for services as the CEO of the Issuer. Read SEC document |
| April 04, 2018 Filed May 1, 2018 15:25 UTC |
Danenberg NoamChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001213900-18-005268 · f4040418danenberg_wizepharma.xml · derivative · entry 2 Danenberg Noam · CIK 0001720898 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,000 shares Expires 2025-04-04 F5 · price: The Stock Option was granted to Danenberg Holdings as compensation for services as the COO of the Issuer. F4 · derivative.exercise_date: The Stock Option is exercisable in twelve equal installments over the three year period from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.